Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1650 participants
OBSERVATIONAL
2020-11-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aggressiveness of Care at the End of Life in Cancer Patients
NCT00980122
Effectiveness of the Supportive and Palliative Care Review Kit (SPARK) for Cancer Patients in the Acute Hospital
NCT03330509
Cost and Medical Care of Patients With Advanced Serious Illness in Singapore (COMPASS) Study
NCT02850640
Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer That Can Be Removed by Surgery
NCT00823667
MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC
NCT06198868
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Through this research, the Quality of Death and Dying Index will be published and it seeks to facilitate monitoring of country-level progress based on domains/sub-domains and indicators used to define quality of death and dying in the discourse on end-of-life care, and within the context of the contrasting realities occurring worldwide. Examining the various trajectories that countries have followed and the experiences of end-of-life care design and delivery by countries from different income groups and based on the viewpoint of diverse stakeholders will provide critical information for metrics development, namely the 2020 Quality of Death and Dying Index
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bereaved caregivers
Caregivers who, in the past two years,have lost a family member or close friend after a brief or extended period of illness or injury
No interventions assigned to this group
Country experts
Qualified individuals (providers, palliative care experts, policy makers) from countries across the globe with knowledge of the phenomenon of interest-end-of-life care.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Current or former policy maker, at the state or national level and having actively engaged in development of policies and strategies on palliative care and/or end-of-life care.
3. Physicians, nurses and/or community health workers who have training to and have actively delivered end-of-life care.
For caregivers
1. In the past two years, lost a family member or close friend after a brief or extended period of illness or injury.
2. Involved in discussions with health care providers concerning the patient's choice of treatments
3. Involved in helping the patient receive medical care, such as accompanying the patient to doctor's visits.
4. Involved in looking after the patient's day to day well-being.
Exclusion Criteria
For all participants
1. Inability to understand English.
2. Minor and not below the age of 21 years.
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Duke-NUS Graduate Medical School
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eric A. Finkelstein
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric A Finkelstein, PhD
Role: PRINCIPAL_INVESTIGATOR
National University of Singapore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Duke-NUS Medical School
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S-20-110
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.